PHOENIX, May 8, 2018 /PRNewswire/ -- Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStem^TM stem cells as a means of reducing/reversing natural aging. 

Previous studies by the Company have demonstrated that AmnioStem^TM cells secrete factors that are capable of rejuvenating aged cells.  By encapsulating the cells outside of the body, so that the cells are in contact with the patient's circulation, the cells are permitted to secrete factors that may reduce aging, without having to inject the cells in the patient. 

The concept of using cells that are growing outside of the body as a means of modifying physiological activities has previously been performed and appears feasible.  Specifically, similar approaches to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure.  A clinical trial demonstrated feasibility of using cell culture of hepatocytes to act as a "liver assist device".  These devices are currently in Phase 3 of clinical trials¹,². 

The filed patent describes a similar approach to those used in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStem^TM amniotic fluid derived stem cells.

"Previous studies from Stanford University³ and Harvard University⁴ have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effects on organs/tissues of aged mice.  Through this patent, we are aiming to recapitulate this effect, in an ethical and technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief Scientific Officer. "What is stunning about the AmnioStem^TM stem cell, which was licensed by the Company from the University of California San Diego, is that it possesses many regenerative features but is collected from non-controversial sources."